X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
KN035 is an investigational PD-L1 antibody, which is currently being evaluated for the treatment of undifferentiated pleomorphic sarcoma & myxofibrosarcoma.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) is being evaluated for the treatment of MSI-H/dMMR Resectable Colon Cancer.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Combination of Opdivo (nivolumab) and Yervoy(Ipilimumab) met the main goal of a late-stage study evaluating it as an initial treatment for patients with advanced hepatocellular carcinoma.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Ultimovacs UV1, which is a hTERT inhibitor, is being evaluated in Phase II clinical trial studies in combination with Ipilimumab and Nivolumab in patients for the treatment of Unresectable or Metastatic Malignant Melanoma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, enema Microbiome Ecosystem TherapyTM for acute, hospital use. It is being evaluated in combination with Ipilimumab for the treatment of metastatic melanoma.
Lead Product(s): MaaT013,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: MaaT013
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
UV1 is an off-the-shelf cancer vaccine designed to induce a specific T cell response against telomerase. It is being evaluated in phase 2 clinical trials in combination with ipilimumab and nivolumab for treatment of patients with unresectable malignant pleural mesothelioma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
UV1 is an off-the-shelf cancer vaccine designed to induce a specific T cell response against telomerase. It is being evaluated in phase 2 clinical trials in combination with ipilimumab and nivolumab for treatment of patients with unresectable malignant pleural mesothelioma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
UV1 is a universal cancer vaccine designed to induce a specific T-cell response against telomerase. It is under phase 2 clinical development in combination with nivolumab and ipilimumab for the treatment of unresectable or metastatic malignant melanoma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is being evaluated in phase 3 clinical development for the treatment of microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Opdivo (Nivolumab) is a PD-1 Inhibitor antibody drug candidate, which is currently being evaluated in combination with "Ipilimumab" for the treatment of patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase, being developed in combination with the checkpoint inhibitors ipilimumab and nivolumab in the treatment of patients with unresectable or metastatic malignant melanoma.
Lead Product(s): UV1,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
UV1 (telomerase inhibitor) in combination with ipilimumab and nivolumab is under phase 2 clinical development for first-line treatment of patients with metastatic malignant melanoma.
Lead Product(s): UV1,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Opdivo (nivolumab), a PD-1 blocking antibody, which is investigated in combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma.
Lead Product(s): Nivolumab,Ipilimumab,Carboplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of malignant melanoma.
Lead Product(s): UV1 Cancer Vaccine,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of mesothelioma.
Lead Product(s): UV1 Cancer Vaccine,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Lead Product(s): SCIB1,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: SCIB1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Scancell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Opdivo (nivolumab) in combination with cisplatin-based chemotherapy Shows statistically significant benefits in OS and PFS compared to standard-of-care cisplatin-based combinations as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alphamab Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of Mesothelioma.
Lead Product(s): UV1 Cancer Vaccine,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
The Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with NSCLC.
Lead Product(s): Nivolumab,Ipilimumab,Carboplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2023
Details:
SQZ-AAC-HPV are derived from RBCs engineered with the Cell Squeeze® technology, designed to take advantage of the natural physiological process of aged RBC clearance by resident APCs in lymphoid organs which primes endogenous T cells to potentially drive antitumor activity.
Lead Product(s): SQZ-AAC-HPV,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: SQZ-AAC-HPV
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
VAC85135, an investigational viral vector-based cancer vaccine for hematological malignancies. The MVA-based component of the vaccine was produced using ProBioGen's AGE1.CR.pIX.
Lead Product(s): VAC85135,Ipilimumab
Therapeutic Area: Oncology Product Name: VAC85135
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
CPI-444 (ciforadenant) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor.
Lead Product(s): Ciforadenant,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: CPI-444
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
The preclinical results showed that Comera’s caffeine-based SQore™ excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic (PK) parameters of ipilimumab when administered subcutaneously.
Lead Product(s): CLS-002,Ipilimumab
Therapeutic Area: Oncology Product Name: CLS-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 is the first approved subcutaneously injected PD-(L)1 inhibitor. Envafolimab is currently being studied in the ENVASARC Phase 2 and a Phase 3 pivotal trial in advanced biliary tract cancer patients.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Gavo-cel (TC-210) demonstrated a disease control rate (DCR) of 77%, which is defined in the Phase 1 portion of the trial as a response or sustained stable disease for at least three months post infusion.
Lead Product(s): Gavocabtagene Autoleucel,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: TC-210
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses.
Lead Product(s): UV1,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The median progression-free survival (mPFS) among patients treated with UV1 and ipilimumab was 6.7 months, and the median overall survival (mOS) was 66.3 months.
Lead Product(s): UV1,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Cabometyx (cabozantinib) in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab.
Lead Product(s): Cabozantinib,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Runway Growth Capital LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 06, 2022
Details:
Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulation with a mAb.
Lead Product(s): Ipilimumab,Caffeine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology, is the first approved subcutaneously injected PD-(L)1 inhibitor.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
Opdivo (nivolumab) and Yervoy (ipilimumab), combination was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Details:
SQore is a caffeine-based excipient when administered as a subcutaneous and combination ipilimumab, a mAb therapy that works to activate the immune system by targeting CTLA-4 to treat melanoma, as a model protein.
Lead Product(s): Caffeine,Ipilimumab
Therapeutic Area: Oncology Product Name: SQore
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
At a prespecified interim analysis for the secondary endpoint of overall survival (OS), the combination of Cabometyx (cabozantinib), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab did not demonstrate a significant benefit.
Lead Product(s): Cabozantinib,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
INITIUM has been designed as a robust comparative study to demonstrate that UV1 substantially enhances outcomes for patients over and above those that can be achieved with checkpoint inhibitors alone.
Lead Product(s): UV1,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
Results from Phase 3 CheckMate -9LA trial demonstrating durable survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy in previously untreated patients with nSCLC.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Opdivo (nivolumab) plus Yervoy-based combinations have shown significant improvements in OS in six Phase 3 clinical trials in five tumors to date: metastatic NSCLC, metastatic melanoma, advanced renal cell carcinoma, and esophageal squamous cell carcinoma.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
XmAb104 is engineered to selectively engage T cells that express both PD-1 and ICOS, important regulators of T cell activity, and we have observed biomarker activity consistent with engagement of both receptors.
Lead Product(s): XmAb23104,Ipilimumab
Therapeutic Area: Oncology Product Name: XmAb104
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
The data demonstrate that UV1 vaccination leads to dynamic immune responses in patients, notably the induction of memory T cells with a cytokine profile involving the production of IFN-gamma and TNF-alpha.
Lead Product(s): UV1,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Tilsotolimod (IMO-2125) has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive immune activation and may, in turn, contribute to tumor suppression and regression.
Lead Product(s): Tilsotolimod,Ipilimumab
Therapeutic Area: Oncology Product Name: IMO-2125
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Opdivo (nivolumab) plus Yervoy-based combinations have shown improvements in OS in six Phase 3 clinical trials in five tumors to date, nSCLC, metastatic melanoma, advanced renal cell carcinoma, malignant pleural mesothelioma and esophageal squamous cell carcinoma.
Lead Product(s): Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Measurable UV1-specific immune response in 91% of patients when combined with checkpoint inhibitor, as compared to 82% and 67% without checkpoint inhibitor.
Lead Product(s): UV1,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes.
Lead Product(s): SD-101,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: SD-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors. Patients must be positive for the human leukocyte antigen serotype HLA-A*02.
Lead Product(s): SQZ-PBMC-HPV,Atezolizumab,Ipilimumab
Therapeutic Area: Oncology Product Name: SQZ-PBMC-HPV
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Scope of patent, when issued, will cover cancer treatments that include UV1 peptide vaccine in combination with an anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody checkpoint inhibitor, it is expected that a patent will issue with a patent term up to at least June 2037.
Lead Product(s): UV1,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Result demonstrated highly tolerable safety profile and significantly higher objective response rate observed in lower weight patients in ENVASARC, to increase dose of envafolimab to 600 mg every three weeks, which is double the original envafolimab dose of 300 mg Q3W.
Lead Product(s): Envafolimab,Ipilimumab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alphamab Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
The NMPA BTD for IBI310 was based on results from First part of a Phase 2 trial of IBI310 in combination with sintilimab showed potential for this combination as a new treatment option for patients in need.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
